These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 24504090

  • 1. Iron chelation: an update.
    Sheth S.
    Curr Opin Hematol; 2014 May; 21(3):179-85. PubMed ID: 24504090
    [Abstract] [Full Text] [Related]

  • 2. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 May; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 3. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM, Taher AT.
    Hemoglobin; 2011 May; 35(5-6):565-73. PubMed ID: 21910602
    [Abstract] [Full Text] [Related]

  • 4. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
    Fernandes JL.
    Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
    [Abstract] [Full Text] [Related]

  • 5. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA.
    Drugs; 2011 Jan 22; 71(2):155-77. PubMed ID: 21275444
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation and treatment of transfusional iron overload in children.
    Ware HM, Kwiatkowski JL.
    Pediatr Clin North Am; 2013 Dec 22; 60(6):1393-406. PubMed ID: 24237978
    [Abstract] [Full Text] [Related]

  • 8. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
    Voskaridou E, Christoulas D, Terpos E.
    Br J Haematol; 2011 Sep 22; 154(5):654-6. PubMed ID: 21615376
    [No Abstract] [Full Text] [Related]

  • 9. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ.
    Expert Opin Drug Saf; 2010 Jul 22; 9(4):633-41. PubMed ID: 20553089
    [Abstract] [Full Text] [Related]

  • 10. Current recommendations for chelation for transfusion-dependent thalassemia.
    Kwiatkowski JL.
    Ann N Y Acad Sci; 2016 Mar 22; 1368(1):107-14. PubMed ID: 27186943
    [Abstract] [Full Text] [Related]

  • 11. Overview of iron chelation therapy with desferrioxamine and deferiprone.
    Cappellini MD, Musallam KM, Taher AT.
    Hemoglobin; 2009 Mar 22; 33 Suppl 1():S58-69. PubMed ID: 20001633
    [Abstract] [Full Text] [Related]

  • 12. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Mar 22; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 13. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Mar 22; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 14. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB, Shah FT.
    Hematol Oncol Clin North Am; 2010 Dec 22; 24(6):1109-30. PubMed ID: 21075283
    [Abstract] [Full Text] [Related]

  • 15. Post-transfusional iron overload in the haemoglobinopathies.
    Thuret I.
    C R Biol; 2013 Mar 22; 336(3):164-72. PubMed ID: 23643400
    [Abstract] [Full Text] [Related]

  • 16. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Mar 22; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 17. The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.
    Kontoghiorghes GJ.
    Hemoglobin; 2011 Mar 22; 35(3):181-5. PubMed ID: 21599430
    [Abstract] [Full Text] [Related]

  • 18. Combined iron chelation therapy.
    Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW.
    Ann N Y Acad Sci; 2010 Aug 22; 1202():79-86. PubMed ID: 20712777
    [Abstract] [Full Text] [Related]

  • 19. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA, Gama S, Gil M, Gano L.
    Hemoglobin; 2008 Aug 22; 32(1-2):147-56. PubMed ID: 18274992
    [Abstract] [Full Text] [Related]

  • 20. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA.
    Blood Rev; 2011 Jan 22; 25(1):17-31. PubMed ID: 21030120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.